MOUNJARO KWIKPEN
Clinical safety rating
cautionComprehensive clinical and safety monograph for MOUNJARO KWIKPEN (MOUNJARO KWIKPEN).
Glucagon-like peptide-1 (GLP-1) receptor agonist; enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and promotes satiety.
| Metabolism | Catabolized via proteolytic degradation by general proteases; not significantly metabolized by CYP450 enzymes. |
| Excretion | Approximately 70% of the administered dose is eliminated via the kidneys (urine) and 30% via the feces (biliary/fecal route). |
| Half-life | Terminal elimination half-life is approximately 5 days (range 4-6 days), supporting once-weekly dosing. Steady state is achieved after 4 weeks of once-weekly administration. |
| Protein binding | >99% bound to plasma proteins, predominantly to albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.5 L/kg, indicating distribution primarily into extracellular fluid and limited tissue binding. |
| Bioavailability | Subcutaneous: Absolute bioavailability is approximately 80% (range 70-90%). |
| Onset of Action | Subcutaneous injection: Onset of glycemic effect is observed within 1 day after the first dose, with peak clinical effect on fasting and postprandial glucose reduction typically seen at 4-8 weeks. |
| Duration of Action | Duration of action is approximately 7 days following a single subcutaneous dose, allowing for once-weekly dosing. Effects on glucose and weight loss persist for several weeks after discontinuation. |
| Molecular Weight | 4815 |
| Action Class | Dual GIP/GLP-1 Receptor Agonist |
Subcutaneous injection once weekly. Initial dose: 2.5 mg for 4 weeks; then increase to 5 mg for at least 4 weeks; further increments of 2.5 mg every 4 weeks as tolerated, up to a maximum of 15 mg once weekly.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). Limited data in severe renal impairment (eGFR <30 mL/min/1.73 m²) or end-stage renal disease; not recommended. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years). No approved pediatric dosing. |
| Geriatric use | No specific dose adjustment required based on age alone. Consider renal function and overall health status; monitor for gastrointestinal effects and volume depletion. |
| 1st trimester | Limited data. Use only if potential benefit justifies risk. Animal studies show fetal risk, but no adequate human studies. |
| 2nd trimester | Use only if benefit outweighs risk. Monitor for maternal hypoglycemia and fetal growth. |
| 3rd trimester | Avoid use during third trimester due to risk of neonatal hypoglycemia and low birth weight. |
Clinical note
Comprehensive clinical and safety monograph for MOUNJARO KWIKPEN (MOUNJARO KWIKPEN).
| Placental transfer | Crosses placenta in animals; expected in humans due to molecular weight ~4815 Da. |
| Breastfeeding | Not recommended breastfeeding while using this drug due to potential for weight loss in infant and lack of safety data. Tirzepatide present in animal milk; unknown in human milk. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | Based on animal studies, tirzepatide may cause fetal harm. GLP-1 receptor agonists have been associated with reduced fetal growth in animal studies. Avoid use in pregnancy, especially during organogenesis (first trimester). Insufficient human data to assess risk in second and third trimesters. Consider discontinuing therapy if pregnancy occurs. |
| Fetal Monitoring | Monitor maternal weight, blood glucose, and metabolic status. Fetal growth should be monitored via ultrasound if conception occurs during therapy. Assess for potential teratogenic effects if exposure occurs in first trimester. No specific fetal monitoring guidelines exist; use standard prenatal care. |
| Fertility Effects | In animal studies, tirzepatide caused an increase in estrous cycle length and decreased fertility at high doses. Human data are lacking. The effect on human fertility is unknown. Women of childbearing potential should use effective contraception. |
■ FDA Black Box Warning
Not applicable (no FDA boxed warning).
| Common Effects | Nausea, Vomiting, Diarrhea, Decreased appetite, Constipation, Dyspepsia, Abdominal pain, Fatigue, Injection site reactions (erythema, pruritus, pain) |
| Serious Effects | Pancreatitis (acute or chronic), Medullary thyroid carcinoma (C-cell tumors, seen in animal studies; contraindicated in patients with personal or family history of MTC or MEN-2), Severe hypoglycemia (especially when used with insulin or sulfonylureas), Acute kidney injury or worsening of chronic renal failure (often due to dehydration from GI effects), Diabetic retinopathy complications (associated with rapid glycemic improvement), Hypersensitivity reactions (angioedema, anaphylaxis), Cholelithiasis and cholecystitis, Suicidal ideation or behavior (rare, monitor) |
Hypersensitivity to tirzepatide or any excipientsPersonal or family history of medullary thyroid carcinomaMultiple endocrine neoplasia syndrome type 2
| Precautions | Risk of thyroid C-cell tumors (medullary thyroid carcinoma); contraindicated in patients with personal or family history of MTC or MEN-2, Acute pancreatitis; discontinue if suspected, Hypoglycemia risk, especially when used with insulin or sulfonylureas, Diabetic retinopathy complications associated with rapid glycemic improvement, Acute kidney injury risk in patients with renal impairment, Gastrointestinal adverse reactions (nausea, vomiting, diarrhea), Heart rate increase; monitor if symptomatic, Immunogenicity and risk of antibody formation |
| Food/Dietary | No significant food interactions. May delay gastric emptying; take oral medications that require rapid absorption at least 1 hour before injection or as directed. |
| Clinical Pearls | MOUNJARO (tirzepatide) is a dual GIP/GLP-1 receptor agonist. Administer once weekly subcutaneously. Titrate dose every 4 weeks based on glycemic response and tolerability. Monitor for pancreatitis, severe GI adverse events, and hypoglycemia (especially with sulfonylureas or insulin). Consider thyroid C-cell tumor risk (black box warning). Not for use in patients with personal/family history of medullary thyroid carcinoma or MEN2. |
| Patient Advice | Inject once weekly on the same day each week, with or without meals. · Rotate injection sites (abdomen, thigh, upper arm). · Store in refrigerator (2-8°C) before first use; after first use, store at room temperature up to 30°C for up to 4 weeks. · Report symptoms of severe abdominal pain (pancreatitis), nausea/vomiting (gastroparesis), or signs of thyroid tumor (neck lump, hoarseness). · Seek medical advice if hypoglycemia symptoms occur when used with insulin or sulfonylureas. |
Loading safety data…